Precision for Value evaluated various considerations that factor into the level of biosimilars uptake, focusing primarily on Europe’s recent introduction of biosimilar anti-tumor necrosis factor drugs (anti-TNF drugs).  Amongst its findings, the authors discovered that discounts do not correlate to the level of biosimilar uptake, and that factors such as doctors’ lack of clinical experience with biosimilars, a nation’s attitude towards the interchangeability of the biosimilars, and geography of payers play into biosimilar popularity. 

Stay tuned to the Big Molecule Watch for further developments.